Intuitive Surgical (ISRG)
Equipos y suministros médicos
The pioneer and leader in robot-assisted surgery (more than 11,100 da Vinci systems installed) fell 39% from its 52-week high after a cut to 2026 procedure growth guidance (to 13.5%-15.5%), with GLP-1 drugs weighing on bariatric surgery and Chinese competition cited as declared headwinds. At ~$372 (TTM P/E ~42×) the base scenario yields ~$351 over five years (-1%): Overvalued — exceptional quality (ROIC ~23% on invested capital) that still commands an elevated multiple despite the reset in expectations.
- Price
- $371.64
- Intrinsic value (5y, base)
- $351
- Total annual return (5y)
- -1.1%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- Dominant franchise with real switching costs (instruments carry a chip that caps their number of uses and are platform-specific; the hospital and surgeon are tied to the training ecosystem) and more than 25 years of accumulated clinical evidence; the installed da Vinci base grew 12% to 11,106 systems, with the da Vinci 5 replacement cycle accelerating sharply: 870 placements in 2025 versus 362 in 2024.
- The stock fell ~39% from its 52-week high after the FY2026 guidance cut for da Vinci procedure growth to 13.5%-15.5% (midpoint ~14.5%), announced alongside the second-quarter 2026 report (~Jul 17, 2026): U.S. growth decelerated from 14% in the first quarter to 12% in the second, with Affordable Care Act premium dynamics, a high-single-digit decline in bariatric cases from GLP-1 drug use, and softening tender activity in China explicitly cited by the company.
- Exceptional quality (ROIC ~23% on the balance sheet's real invested capital, no financial debt) but at a P/E of ~42× TTM net income; the base scenario projects multiple compression toward ~20× (the med-tech archetype band), which barely offsets future earnings growth — No margin of safety: the price already discounts a demanding scenario.
Intrinsic value — two valuation methods
By both methods, the value today (DCF $371 · Multiples $282) is below the market price ($372).
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $372 trades ~31.9% above its value discounted to today (~$282); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$175.
Thesis
The business
Intuitive Surgical is the pioneer and leader in robot-assisted surgery, with a recurring-instrument (razor-and-blades) model built on an installed base of more than 11,100 da Vinci systems, real switching costs, and a depth of clinical evidence no competitor yet matches. Business quality is exceptional: ROIC ~23% on real invested capital, no financial debt, and operating margins above 31% with a trend toward further expansion.
The valuation
Valued on P/E over net income, with an exit multiple derived from the med-tech archetype (16-22× band). At ~$372 the stock trades at a TTM P/E of ~42×, well above the terminal band, because the market kept paying for growth above what the company itself guided for 2026. The base scenario starts the growth path at the procedure guidance (~15% revenue growth in year 1, not the historical trajectory of +20.7%) and decelerates smoothly to ~11% by year 5, with the multiple compressing from ~42× to ~20×. That yields ~$351/share over five years → a CAGR of ~-1%.
The margin of safety
No margin of safety: the price already discounts a demanding scenario. The multiple compression demanded by the med-tech archetype (20× terminal versus ~42× at entry) absorbs nearly all of the projected earnings growth, leaving a base return barely above or below zero. The verdict is Overvalued: an outstanding-quality business that still does not offer the margin of safety the method requires, even after the 39% decline from the high.
What to watch
The central disconfirming test is whether procedure growth genuinely converges toward the guided midpoint (~14.5%) or whether the pressures — GLP-1 drugs on bariatric surgery, competition and price regulation in China, Affordable Care Act premium dynamics on U.S. utilization, and the cost of tariffs (US$63 million in 2025, with the company warning they will keep rising in 2026) — worsen beyond what was guided. On the other side, watch the pace of the da Vinci 5 replacement cycle (870 placements in 2025, more than double 2024) and Ion adoption, which could sustain growth above the conservative guidance.
Educational / informational. Does not constitute investment advice.